Bosentan and Pulmonary Hypertension Caused by COVID-19: A Pilot Randomized Double-blind Clinical Study.
Fahime ShokrollahiAli PazokiAbbas AllamiShahin AliakbariKimia Rahimi ArdaliPublished in: Current vascular pharmacology (2024)
This study provided a mixed perspective on the use of bosentan therapy in patients with COVID-19-related PH. Bosentan effectively reduced in-hospital mortality and improved echocardiographic measures. However, the treatment group showed an increased requirement for supplemental oxygen therapy and long-term mortality. Further studies with larger sample sizes are necessary to elucidate the effects of bosentan in PH following COVID-19.
Keyphrases
- pulmonary arterial hypertension
- pulmonary hypertension
- coronavirus disease
- sars cov
- pulmonary artery
- double blind
- clinical trial
- left ventricular
- mitral valve
- randomized controlled trial
- cardiovascular events
- risk factors
- left atrial
- cardiovascular disease
- respiratory syndrome coronavirus
- study protocol
- coronary artery disease
- phase iii
- case control
- open label
- combination therapy
- smoking cessation
- drug induced